Btk inhibition treats TLR7/IFN driven murine lupus
详细信息 查看全文
- 作者：Andrew T. Bendera ; Andrew.bender@emdserono.com" class="auth_mail" title="E-mail the corresponding author ; Albertina Pereiraa ; Kai Fua ; Eileen Samya ; Yin Wua ; Lesley Liu-Bujalskib ; Richard Caldwellb ; Yi-Ying Chenb ; Hui Tianb ; Federica Morandic ; Jared Headc ; Ursula Koehlerd ; Melinda Genesta ; Shinji L. Okitsua ; Daigen Xua ; Roland Grenningloha
- 关键词：Btk ; Bruton's tyrosine kinase ; TLR7 ; Toll-like receptor 7 ; BCR ; B cell receptor ; FcR ; Fc receptor ; SLE ; systemic lupus erythematosus ; IFN ; interferon ; FACS ; fluorescence-activated cell sorting ; MMF ; mycophenolate mofetil
- 刊名：Clinical Immunology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：164
- 期：Complete
- 页码：65-77
- 全文大小：1983 K
文摘
- •
Btk inhibition reduces autoantibodies, nephritis, and mortality in BXSB-Yaa lupus mice.
- •
Btk inhibition suppresses arthritis development in pristane-induced mouse lupus.
- •
In lupus mice, arthritis can be suppressed without a significant reduction in autoantibodies or IFN.
- •
Btk inhibition can block activation of human macrophages by immune complexes and TLR7.
- •
Btk inhibition can provide therapeutic benefit to SLE patients by affecting both BCR and FcR signaling.